Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Boule Diagnostics AB (BOUL.ST)
SEK3.76
-0.08 (-2.08%)
SE STO Healthcare Medical - Specialties
Address
Domnarvsgatan 4 163 53
Spånga, AB, SE
Spånga, AB, SE
CEO
Torben Nielsen
Website
boule.com
IPO
2011-06-23
ISIN SE0011231158
Description
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK3.76
-0.08 (-2.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
42.8K
Beta
0.18
Float Shares
28.84M
Free Float %
74.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.21% | -2.35% | -3.49% | -22.79% | -46.45% | -37.12% | -58.40% | -70.25% | -94.26% | -84.74% | -71.68% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.76
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.79
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%-12.3% Q1'26: -10.0% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+98.3% ★ Q1'26: -40.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-3.0% Q1'26: +10.3% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+5.2% Q1'26: -9.3% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+3.8% Q1'26: -10.0% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%-2.2% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×10.12× Q1'26: -5.90× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
331.41M
est: 324.30M (+2.2%)
|
400.74M
est: 388.40M (+3.2%)
|
427.79M
est: 431.00M (-0.7%)
|
424.40M
est: 433.43M (-2.1%)
|
498.92M
est: 492.80M (+1.2%)
|
400.46M
est: 409.01M (-2.1%)
|
463.34M
est: 438.82M (+5.6%)
|
548.09M
est: 545.39M (+0.5%)
|
571.33M
est: 575.11M (-0.7%)
|
558.60M
est: 556.04M (+0.5%)
|
489.70M
est: 503.09M (-2.7%)
|
453.10M
453.10M – 453.10M
-9.9% YoY
|
483.30M
483.30M – 483.30M
+6.7% YoY
|
512.60M
512.60M – 512.60M
+6.1% YoY
|
| EBITDA |
26.65M
est: -4.83M (+651.6%)
|
57.73M
est: -5.79M (+1,097.6%)
|
66.58M
est: -6.42M (+1,136.9%)
|
64.91M
est: -6.46M (+1,105.2%)
|
92.98M
est: -7.34M (+1,366.4%)
|
16.98M
est: -6.09M (+378.6%)
|
55.69M
est: -6.54M (+951.9%)
|
57.85M
est: -8.13M (+811.9%)
|
65.98M
est: -8.57M (+870.1%)
|
-255.90M
est: -7.28M (-3,417.1%)
|
25.20M
est: -6.58M (+482.8%)
|
-5.93M
-5.93M – -5.93M
+9.9% YoY
|
-6.32M
-6.32M – -6.32M
-6.7% YoY
|
-6.71M
-6.71M – -6.71M
-6.1% YoY
|
| EBIT |
21.84M
est: -20.00M (+209.2%)
|
47.84M
est: -23.96M (+299.7%)
|
53.61M
est: -26.58M (+301.7%)
|
55.22M
est: -26.73M (+306.5%)
|
54.80M
est: -30.39M (+280.3%)
|
-44.96M
est: -25.23M (-78.2%)
|
34.22M
est: -27.07M (+226.4%)
|
30.67M
est: -33.64M (+191.2%)
|
41.36M
est: -35.47M (+216.6%)
|
-255.90M
est: -27.30M (-837.3%)
|
25.20M
est: -24.70M (+202.0%)
|
-22.25M
-22.25M – -22.25M
+9.9% YoY
|
-23.73M
-23.73M – -23.73M
-6.7% YoY
|
-25.17M
-25.17M – -25.17M
-6.1% YoY
|
| Net Income |
15.35M
est: 42.35M (-63.7%)
|
36.03M
est: 63.73M (-43.5%)
|
37.24M
est: 61.05M (-39.0%)
|
41.03M
est: 68.50M (-40.1%)
|
37.55M
est: 56.26M (-33.3%)
|
-47.97M
est: -47.29M (-1.4%)
|
23.27M
est: 20.65M (+12.7%)
|
12.73M
est: 26.22M (-51.5%)
|
24.98M
est: 24.30M (+2.8%)
|
-223.30M
est: -30.59M (-630.0%)
|
-3.80M
est: 22.97M (-116.5%)
|
-9.50M
-9.50M – -9.50M
-141.4% YoY
|
8.36M
8.36M – 8.36M
+188.0% YoY
|
16.72M
16.72M – 16.72M
+100.0% YoY
|
| SGA |
89.07M
est: 88.05M (+1.2%)
|
103.57M
est: 105.45M (-1.8%)
|
115.54M
est: 117.01M (-1.3%)
|
109.64M
est: 117.67M (-6.8%)
|
128.11M
est: 133.79M (-4.2%)
|
110.94M
est: 111.04M (-0.1%)
|
120.15M
est: 119.14M (+0.9%)
|
143.60M
est: 148.07M (-3.0%)
|
153.35M
est: 156.14M (-1.8%)
|
162.40M
est: 149.61M (+8.5%)
|
129.70M
est: 135.36M (-4.2%)
|
121.91M
121.91M – 121.91M
-9.9% YoY
|
130.04M
130.04M – 130.04M
+6.7% YoY
|
137.92M
137.92M – 137.92M
+6.1% YoY
|
| EPS |
0.58
est: 1.09 (-46.8%)
|
1.35
est: 1.64 (-17.7%)
|
1.36
est: 1.57 (-13.5%)
|
1.50
est: 1.76 (-15.0%)
|
1.37
est: 1.45 (-5.4%)
|
-1.75
est: -1.22 (-43.7%)
|
0.85
est: 0.53 (+59.8%)
|
0.46
est: 0.68 (-31.9%)
|
0.64
est: 0.63 (+2.3%)
|
-5.75
est: -1.51 (-279.7%)
|
-0.10
est: 0.60 (-116.5%)
|
-0.25
-0.25 – -0.25
-141.4% YoY
|
0.22
0.22 – 0.22
+188.0% YoY
|
0.44
0.44 – 0.44
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
11.63M
OE per share TTM
0.29
Owner's Yield
9.02%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
10.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
117.2K
Shares Outstanding
38.83M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Torben Nielsen | Chief Executive Officer & Group President | 5M | male |
| Eva Sperling | Chief of Staff | — | female |
| Lucy Yehiayan | Chief Technology Officer | — | female |
| Eduardo Pagani | Chief Operating Officer | — | male |
| Michael af Winklerfelt | Chief Financial Officer | — | male |
| Simonetta Tumbiolo | Chief Commercial Officer | — | female |
| Michael Elliott | Chief OEM Business Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BOUL.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
